IMNN Latest Press Releases

-- November 6, 2026 --

IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer Globe Newswire 9:00 AM

-- November 2, 2026 --

IMUNON to Hold Third Quarter 2026 Financial Results and Business Update Conference Call on Thursday, November 12, 2026 Globe Newswire 8:30 AM

-- October 21, 2026 --

IMUNON Announces Strategic Sale of ThermoDox Globe Newswire 8:15 AM

-- October 8, 2026 --

IMUNON to Participate in Upcoming Investor Conferences Globe Newswire 9:00 AM

-- September 29, 2026 --

IMUNON Converts $1.2 Million of Debt-to-Equity Globe Newswire 8:00 AM

-- September 24, 2026 --

IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan Globe Newswire 8:05 AM

-- September 22, 2026 --

IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review Globe Newswire 8:05 AM

-- September 10, 2026 --

IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001 Globe Newswire 9:30 AM

-- September 9, 2026 --

IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress Globe Newswire 8:30 AM

-- August 26, 2026 --

IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001 Globe Newswire 8:30 AM

-- August 11, 2026 --

IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update Globe Newswire 8:00 AM

-- August 4, 2026 --

IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026 Globe Newswire 8:00 AM

-- July 30, 2026 --

IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer Globe Newswire 9:00 AM

-- July 23, 2026 --

IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development Globe Newswire 9:25 AM

-- July 21, 2026 --

IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer Globe Newswire 9:00 AM

-- June 26, 2026 --

Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing Globe Newswire 8:35 AM

-- June 23, 2026 --

Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th Globe Newswire 8:35 AM

IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification Globe Newswire 8:00 AM

-- June 22, 2026 --

IMUNON to Present at the Life Sciences Investor Forum on June 25th Globe Newswire 4:15 PM

Market Data Delayed 15 Minutes